Abstract: Electronic devices may be provided with displays that have polarizers. A polarizer may have a polymer layer that has a portion covered with a dichroic dye to form a polarized region and a portion that is free of dichroic dye to form an unpolarized region. The unpolarized region may be formed by masking the polymer layer during a dye coating process. Masks may be formed from polymers. The shape of the mask may define the shape of the unpolarized region. The mask may be left in place within the polarizer or may be removed from the polarizer during fabrication. Unpolarized regions may also be formed by light bleaching, chemical bleaching, and material removal techniques. Bleached areas may be chemically stabilized. A moisture barrier layer may be incorporated into the polarizer to help prevent the unpolarized region from reverting to a polarized state.

Abstract: The present disclosure provides compounds of any one of Formulae (I), (II), and (III). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: The present invention provides compounds of Formula (II) (e.g., compounds of Formula (I)), and pharmaceutically compositions thereof. Compounds of Formula (II) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.

Abstract: Embodiments related to an electronic device having an adaptive input row. The adaptive input row may be positioned within an opening of a device and include a cover for receiving a touch and a display that is configured to present an adaptable set of indicia. The adaptive input row may also include one or more sensors for detecting the location of a touch and/or the magnitude of a force of the touch. The adaptive input row may be positioned adjacent or proximate to a keyboard of the electronic device.

Abstract: An electronic device may generate content that is to be displayed on a display. The display may have an array of liquid crystal display pixels for displaying image frames of the content. The display may be operated in at least a normal viewing mode, a privacy mode, an outdoor viewing mode, and a power saving mode. The different view modes may exhibit different viewing angles. In one configuration, the display may include a backlight unit that generates a collimated light source and that includes a switchable diffuser film for selectively scattering the collimated light source depending on the current viewing mode of the display. In another configuration, the display may include a backlight unit that generates a scattered light source that includes a switchable microarray structure such as a switchable mirror structure or a tunable microlens array for selectively collimating the scattered light source depending on the current viewing mode.

Abstract: Aspects of the subject technology relate to control circuitry for light-emitting diodes. The control circuitry may operate a light-emitting diode using a multi-peak pulse-width-modulation signal. The control circuitry may include a multi-stage driver having a relatively larger driver stage for providing a direct current through a light-emitting diode and a relatively smaller driver stage configured to cooperate with a pulse-width-modulation controller to pulse-width-modulate a current through the light-emitting diode.

Abstract: Aspects of the subject technology relate to control circuitry for light-emitting diodes. The control circuitry may operate a light-emitting diode using a multi-peak pulse-width-modulation signal. The control circuitry may include a multi-stage driver having a relatively larger driver stage for providing a direct current through a light-emitting diode and a relatively smaller driver stage configured to cooperate with a pulse-width-modulation controller to pulse-width-modulate a current through the light-emitting diode.

Abstract: A computing device is disclosed. The computing device may include a display, a processor in communication with the display and an enclosure connected to the display. The computing device may also include an input/output (I/O) device in communication with the processor. The I/O device may also be connected to the enclosure. Additionally, the I/O device may include a modifiable display that may substantially match the appearance of the enclosure.

Abstract: The present invention provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.

Abstract: An electronic device and method for text processing, the electronic device comprises a processor (100), and the processor is configured to: determine a correlation between a first text vector and a second text vector, wherein the first text vector and the second text vector are multi-dimensional, real number vectors generated on the basis of a same text, respectively; obtain, according to the correlation, a third text vector representing the text, wherein a vector space in which the third text vector is located is correlated to vector spaces in which first text and second text vectors are located. The electronic device and method of the present invention can be used to create a text-feature representation model which represents text features by combining a plurality of view angles, thereby improving the performance of natural language processing.

Abstract: An electronic device may have a main display and an ancillary display. The device may also have a backlit keyboard with glyphs. An ambient light sensor may measure ambient light levels. Control circuitry in the laptop computer may adjust the color cast of content on the ancillary display depending on whether the content contains glyphs or other input display content or whether the content contains images, color gradients, or other output display content. Input display content may be matched in color cast to the color cast of the glyphs, which may be determined based on backlight status and/or measured ambient light information. Output content may be color matched to the main display.

Abstract: The present invention provides bivalent inhibitors of BET bromodomains, such as compounds of Formulae (I), (II), (III), (IV), (V) and (VI). Some bromdomain-containing proteins (e.g., BRD4) have a tandem bromodomain primary structure comprising more than one bromodomain binding site (e.g., BRD4 comprises BD1 and BD2). Bivalent inhibitors of BET bromodomains provided herein can target bromodomains through advantageous multivalent interactions, and can therefore can be to treat diseases comprising the inventive compounds, as well as methods of using the inventive compounds.

Abstract: The present invention provides compounds of Formula (II) (e.g., compounds of Formula (I)), and pharmaceutically compositions thereof. Compounds of Formula (II) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.

Abstract: A display may store extended display identification data for communicating the capabilities of the display to a source device such as a graphics processing unit. The extended display identification data may include a red primary color value, a green primary color value, and a blue primary color value. The primary color values in the extended display identification data may be determined during manufacturing. For example, a light sensor may measure the native primary colors of the display, and calibration computing equipment may determine if the native primary colors of the display are within a target color gamut. If the native primary colors of the display are outside of the target color gamut by an amount larger than a threshold, the primary color values in the extended display identification data may be adjusted to account for the color variation.

Abstract: A computing device is disclosed. The computing device may include a display, a processor in communication with the display and an enclosure connected to the display. The computing device may also include an input/output (I/O) device in communication with the processor. The I/O device may also be connected to the enclosure. Additionally, the I/O device may include a modifiable display that may substantially match the appearance of the enclosure.

Abstract: A milling cutter is configured to process an edge of a workpiece to a required profile. The required profile includes a first portion and a second portion coupled to the first portion. The milling cutter includes a shank having a central axis, at least one first cutting edge, and at least one second cutting edge. The first cutting edge is configured to rotate around the central axis of the shank along a first rotation path to process the first portion of the predetermined profile, and the second cutting edge is configured to rotate around the central axis of the shank along a second rotation path to process the second portion of the predetermined profile. The first rotation path is different from, and connected to the second rotation path.

Abstract: The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1 and/or EZH2 inhibitors.

Abstract: The invention relates to novel derivatives of thapsigargin that are chemically modified with a group that targets a cell surface-expressed receptor, and pharmaceutical preparations thereof. The invention further relates to methods of treating diseases such as cancer using the compounds of the invention.

Abstract: An electronic device may be provided with a display. Backlight structures may be used to provide backlight for the display. The backlight structures may include a light guide plate. The light guide plate may include a planar extended portion that guides light along the back of the display and an integrated edge reflector along one or more edges of the planar extended portion. The planar extended portion and the integrated edge reflector may be formed from respective first and second shots of material. The integrated edge reflector may be formed from a polymer material with embedded reflective structures such as glass microbeads or other oxide particles. The backlight structures may include a reflective layer that is attached to the integrated edge reflector of the light guide plate using adhesive. The display may include active display pixels formed over a portion of the integrated edge reflector.

Abstract: The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail).